What’s Coming Next in Relapsed/Refractory Multiple Myeloma
Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Considering Patient-, Treatment-, and Disease-Related Factors in Myeloma
Factors to consider when choosing the optimal treatment approach after the first relapse of multiple myeloma.
Selecting Appropriate Therapy for Patients With Relapsed/Refractory Multiple Myeloma
James Hoffman, MD, and Joshua Richter, MD, discuss the IKEMA study, the appropriate selection of therapy, and the differences between various options.
Analysis of the BOSTON Trial
Experts in the field of multiple myeloma discuss the BOSTON trial, the study design, and the benefits of using selinexor in a patient after CAR T-cell therapy.
Evolving Treatment Options for Relapsed/Refractory Multiple Myeloma
Drs Hoffman and Richter discuss a promising new treatment for patients with relapsed/refractory multiple myeloma who are not eligible for a clinical trial after 4 lines of therapy.
Clinical Data for Selinexor Use in Myeloma
Experts in treating multiple myeloma discuss the trials that led to the approval of selinexor with bortezomib and dexamethasone, and which patient population would benefit from treatment, as well as the dosing, safety, and efficacy.
Newly Approved Regimens for Relapsed/Refractory Multiple Myeloma
Key opinion leaders discuss newly approved agents and their impact on treatment decisions for relapsed/refractory multiple myeloma.
Risk of Myeloma Relapse After Frontline Therapy
Myeloma experts, Drs James Hoffman and Joshua Richter, discuss the factors that increase a patient’s risk of relapse after frontline treatment for multiple myeloma.
Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden
Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis
MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome
2 Clarke Drive Cranbury, NJ 08512